Faculty, Staff and Student Publications
Publication Date
11-1-2024
Journal
Virchows Archiv
Abstract
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse. Therefore, there is a need for novel therapies that can improve remission rates in patients with relapsed and refractory AML. CD70 is the natural ligand for CD27 (a member of the TNF superfamily) and appears to be a promising therapeutic target. Consequently, there is considerable interest in developing chimeric antigen receptor (CAR) T-cell therapy products that can specifically target CD70 in various neoplasms, including AML. In this study, we employed routine diagnostic techniques, such as immunohistochemistry and flow cytometry, to investigate the expression of CD70 in bone marrow samples from treatment-naïve and relapsed AML patients after hypomethylating agents (HMA). Also, we evaluated the impact of HMA on CD70 expression and examined CD70 expression in various leukemic cell subsets and normal hematopoietic progenitors.
Keywords
Humans, CD27 Ligand, Leukemia, Myeloid, Acute, Middle Aged, Male, Female, Adult, Aged, Recurrence, DNA Methylation, Flow Cytometry, Young Adult, Immunohistochemistry
DOI
10.1007/s00428-024-03741-8
PMID
38388965
PMCID
PMC11564407
PubMedCentral® Posted Date
2-22-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons